Hair loss for women can be especially devastating to their mental health, with the American Hair Loss Association calling hair loss in women a serious life-altering condition.
Harnessing advancements in molecular, stem cell and hair biology, Arbor Life Labs have developed the patent-pending botanical Replenology hair system to promote hair growth, prevent hair loss and activate dormant hair follicles.
Arbor’s Replenology (ALRV5XR) is a novel treatment aiming to regenerate a normal hair phenotype by targeting multiple molecular pathways linked to hair growth promotion and hair follicle stem cell activation.
The company recently announced the results of a 24-week clinical trial that evaluated the safety and efficacy of ALRV5XR in terminal hair (TH) regrowth in women with androgenetic alopecia (AGA) or telogen effluvium (TE). The research, funded by Arbor Life Labs, was published in the journal EClinicalMedicine as well as The Lancet’s Specialty Collection on Regenerative Medicine.
This randomized, double-blind, placebo-controlled trial included 39 healthy women 18-65 years of age with AGA or TE. The participants were allocated in a 1:1 ratio into ALRV5XR or placebo treatment groups using a random number table. The treatment regimen included one oral supplement capsule twice per day, along with daily use of a shampoo, conditioner and follicle serum. Masked dermatologist assessments, phototrichograms and blood samples were obtained at baseline, 12 and 24 weeks. Participants were given a masked treatment regimen of oral capsules, shampoo, conditioner and follicle serum for daily administration.
The researchers found that ALRV5XR increased total scalp hair density by 33.9 hairs/cm and 18.6% more than the placebo. This result is a four-fold improvement in hair growth and response rates when compared to published results of trials using standard therapy. The researchers also found hair regrowth was accelerated during the trial.
“In women with AGA or TE, ALRV5XR treatment significantly increased hair regrowth without adverse events. ALRV5XR displayed a multi-fold improved efficacy and response rate when compared to published trials of standard therapy. Progressive acceleration of TH regrowth suggests regeneration of the structure and function of non-productive telogen follicles and prolonged treatment may restore a normal hair phenotype,” the authors concluded, adding that ALRV5XR has the potential to become a new standard of care for women with hairloss. “Future research should focus on evaluation of its long-term safety and efficacy. Moreover, further elucidation of the mechanisms underlying ALRV5XR action might justify its utility in other ageing tissues.”
“The clinical significance of this trial’s results is a major milestone for the company,” said Peter Feldman, CEO of Arbor and first author of the study. “Since 1995, scientists have said that there is no single molecule, either orally or topically delivered, that can solve the problem of hair loss. Likewise, it has been stated that there is no single botanical that can target all aspects of hair follicle health. The Replenology formulation, however, is a nutrient combination that supports the requirements of healthy functioning hair follicles.”
Arbor Life Labs had a similar outcome when they studied the use of ALRV5XR on men.
“Safety and efficacy of ALRV5XR in women with androgenetic alopecia or telogen effluvium: A randomised, double-blinded, placebo-controlled clinical trial”
Authors: P. Feldman et al